AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has entered into a collaboration with a biotech company developing antibodies targeting peripheral neural response, funded by a top-tier European Venture Capital firm.
Under the terms of the agreement, AbCheck will apply its proprietary technology suite comprising a tailored combination of state-of-the-art antibody discovery technologies to delivering antibodies against an undisclosed target with a particularly challenging Target Product Profile. AbCheck’s high-class drug discovery platform centered on the Company’s unique microfluidics technology, is designed to overcome target-specific challenges and improve success rates for drug discovery campaigns, paving the way towards next generation protein therapeutics.
https://finance.yahoo.com/news/abcheck-announces-collaboration-apply-microfluidics-100000546.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.